For the first nine months of 2025, sales rose slightly to €9.58 billion, compared to €9.54 billion in the same period last year dsm-firmenich has reported resilient performance for the…

For the first nine months of 2025, sales rose slightly to €9.58 billion, compared to €9.54 billion in the same period last year

dsm-firmenich has reported resilient performance for the third quarter of 2025, supported by steady demand across its key markets in nutrition, health, and beauty. While quarterly sales dipped 5 per cent to €3.07 billion, the company posted a significant increase in profitability, with Adjusted EBITDA holding steady at €540 million, reflecting continued margin improvement.

For the first nine months of 2025, sales rose slightly to €9.58 billion, compared to €9.54 billion in the same period last year. Adjusted EBITDA surged 19 per cent year-on-year to €1.8 billion, with margins expanding to 18.8 per cent, up from 15.9 per cent in 2024.

CEO Dimitri de Vreeze said the company’s performance demonstrates the strength of its diversified portfolio and science-led innovation strategy.

“Our key strategic end-markets continue to demonstrate strong fundamentals, underpinned by megatrends in nutrition, health, and beauty. This positions us well to deliver strong growth through our unique portfolio, market-leading science-led capabilities, and broad geographic footprint,” de Vreeze said.

He added that despite a challenging macroeconomic environment and a tough comparison base, dsm-firmenich achieved 2 per cent organic sales growth in the quarter and a “strong step-up” in Adjusted EBITDA.

Updated 2025 Outlook

The company has revised its full-year 2025 Adjusted EBITDA guidance to around €2.3 billion, incorporating an estimated €90 million negative foreign exchange impact and approximately €50 million lower contribution from vitamins in its Animal Nutrition & Health (ANH) business.

De Vreeze reaffirmed expectations for a €300 million increase in Adjusted EBITDA versus 2024 on a comparable basis, supported by organic growth, merger synergies, and cost efficiency programs.

ANH Divestment and Share Buyback Progress

dsm-firmenich reiterated its commitment to exit the Animal Nutrition & Health business, noting that while the divestment process is taking longer than expected, it aims to conclude the transaction in the fourth quarter of 2025.

In addition, the company continues to advance its €1 billion share buyback program, launched on April 1, 2025, to reduce issued capital. As of October 28, approximately 85 per cent of the program had been completed.

dsm-firmenich said it remains confident in its long-term strategy to drive sustainable growth through innovation in nutrition, health, and beauty, while continuing to deliver value for shareholders.